Back to Research Hub
Alnylam Pharmaceuticals, Inc.
ALNY
$297.69+5.53 (+1.89%)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
StreetsValue research for Alnylam Pharmaceuticals, Inc. (ALNY)
Members get the full report for Alnylam Pharmaceuticals, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.